comparemela.com
Home
Live Updates
FDA Grants Accelerated Approval to Tovorafenib for Pediatric Patients With BRAF-Mutated LGG : comparemela.com
FDA Grants Accelerated Approval to Tovorafenib for Pediatric Patients With BRAF-Mutated LGG
Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.
Related Keywords
Eric Bouffet
,
Roger Packer
,
Day One Biopharmaceuticals Inc
,
Novartis
,
Behavioral Medicine At Children National Hospital
,
Us Food Drug Administration
,
Alex Mit
,
Young Adult Patients With Relapsed
,
Progressive Low Grade Glioma
,
Advance Solid Tumors
,
Day One Biopharmaceuticals
,
Behavioral Medicine
,
National Hospital
,
Trametinib Combination Receives
,
Pediatric Low Grade Glioma
,
Pediatric Patients With Low Grade
,
comparemela.com © 2020. All Rights Reserved.